Department of Dermatology, Royal Melbourne Hospital, Parkville, Victoria, Australia.
Department of Medicine, University of Melbourne, Parkville, Victoria, Australia.
Australas J Dermatol. 2023 Nov;64(4):e352-e356. doi: 10.1111/ajd.14139. Epub 2023 Jul 31.
Upadacitinib is a selective Janus kinase-1 (JAK-1) inhibitor that has been shown in clinical trials to be effective for the treatment of moderate-to-severe atopic dermatitis (AD). This study aimed to evaluate the real-world experience of patients with AD treated with upadacitinib in a single-centre Australian cohort. Our study revealed a higher propensity for herpetic infections compared with previous randomised controlled trials (RCTs).
乌帕替尼是一种选择性 Janus 激酶-1（JAK-1）抑制剂，临床试验已证明其对中重度特应性皮炎（AD）的治疗有效。本研究旨在评估澳大利亚单中心队列中接受乌帕替尼治疗的 AD 患者的真实世界经验。与之前的随机对照试验（RCT）相比，我们的研究显示疱疹感染的倾向性更高。
